Blood friends new life, not to live up to Shaohua I Chu sail · Starting again, the tour of the frontier progress of hemophilia (Tianjin Station) was successfully held
Time of Update: 2022-10-01
Figure 6 Professor Zhou Zeping shares the latest database update of hemophiliaPoint 2: Emmy Saizumab helps improve the management confidence of hemophilia patientsIn terms of surgery, a number of clinical and real-world studies have shown that in patients receiving prophylactic treatment with Emmy Saizumab, minor surgery can be safely performed without additional coagulation factor supplementation; Major surgery is safe when used in combination with other hemostatic agents.
Voice of China's novel third-generation EGFR-TKI SH-1028 in second-line therapy for EGFR T790M mutation-positive NSCLC
Time of Update: 2022-09-08
This issue bringsZhou CaicunThe professor's team recently published a phase II clinical study in JTO to explore the efficacy and safety of a novel third-generation EGFR TKI (SH-1028) in patients with EGFR T790M-positive mutant NSCLC .
Professor Feng Ru: PI3K Inhibitors Help FL and MZL "No Chemotherapy", Bringing Survival Benefits to Patients
Time of Update: 2022-04-29
The SAKK 35/10 phase II study showed that the R2 regimen had an overall response rate (ORR) of 81% and a median PFS of 5 years, which was superior to rituximab monotherapy .
Haematol: Methotrexate-Associated Central Neurotoxicity: Clinical Characteristics, Risk Factors, and Genome-Wide Association Studies in Children Treated with Acute Lymphoblastic Leukemia
Time of Update: 2022-04-24
Children receiving intrathecal (IT) methotrexate (MTX) were permanently missed after symptomatic MTX neurotoxicity (n=48) compared with children receiving IT MTX who continued to receive ALL in the central nervous system (CNS) There was an increased risk of recurrence (n=1,174) ( P =0.
ALS new drug research and development both suffered setbacks: Biogen/Ionis terminated the phase I trial of Amylyx's drug listing, which was questioned by FDA
Time of Update: 2022-04-21
On March 28, Biogen and its partner Ionis Pharmaceuticals released the first-line results of the Phase I clinical trial of BIIB078 .
The FDA questioned the company's ALS treatment AMX0035 on March 28, arguing that data on the drug's effectiveness were inconclusive .
"Nature Medicine" Silencing a gene accidentally found clues to the treatment of ALS
Time of Update: 2022-02-18
By studying patients' brain and spinal cord tissue, the researchers found that the drug silenced FUS throughout the nervous system and reversed the toxicity of FUS and other disease-related proteins .
How to treat fatty liver
Time of Update: 2021-12-03
SAB gene activation and increased protein levels are related to liver disease progression in mice and human fatty liver .
But Neil Kaprowitz, a professor of medicine at the Keck Medical Center, said that even after being fed a high-fat, high-sugar diet for one year, the liver of mice has already developed inflammation and fibrosis.
The effect of exercise on the disease progression of patients with localized prostate cancer
Time of Update: 2021-11-15
In order to improve cardiovascular health and delay the progression of prostate cancer, researchers evaluated the impact of high-intensity interval training (HIIT) on low- to intermediate-risk patients who are suitable for active monitoring .
MyPathway study proves that HER2 is a viable target for cholangiocarcinoma
Time of Update: 2021-10-21
Comment This trial shows that in HER2-positive cholangiocarcinoma patients, HER2 is a viable target for the development of new drugs .
Changzhou develops closed-circuit boiling dryer in one step
Time of Update: 2021-10-20
Recently, Changzhou Yibu Drying Equipment Co. , Ltd. has successfully developed FGBX series closed-circuit boiling dryers using advanced technologies such as closed-circuit and boiling drying. It w
Merck's K-drug combination therapy for first-line treatment of esophageal cancer receives positive opinions from EU CHMP
Time of Update: 2021-06-01
Reference source: Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
Abbott's TriClip G4 tricuspid valve repair system obtains EU CE certification
Time of Update: 2021-05-02
A few days ago, Abbott's latest generation of upgraded minimally invasive transcatheter tricuspid valve repair system TriClip G4 has obtained CE mark approval from European regulatory agencies to help prevent blood leakage from the patient's heart tricuspid valve.
Lancet respir med: Analbinin does not improve clinical symptoms in patients with mild to moderate neocycline pneumonia
Time of Update: 2021-01-31
the 14th day, 28 patients in the anabinin group needed mechanical aeration or death, while 28 people in the placebo group (47 percent vs.
study, antatin did not improve symptoms in patients with mild to moderate neo-coronary pneumonia.
Nano-carrier precision delivery to kill melanoma
Time of Update: 2020-12-06
Technology Daily (Reporter Mao Li) Tel Aviv University in Israel recently said that the university's research team designed a nano-carrier drug system for the treatment of skin melanoma.
Because polyglutamate makes up the nanocarbon itself biodegradable, the hybrid drugs it carries will attack cancer cells directly and simultaneously when released.
BMJ: Have immunosuppressant side effects? Scientists have found that Treg cells suppress immunity
Time of Update: 2020-11-06
analysis of biomarkers in patients in the nTreg treatment group and control group, this study shows that this nTreg is safer, has good tolerance, and can reduce the use of immunosuppressants.